- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Thank you
Unique collaboration between OPO and transplant center initiated in XVIVO’s US clinical trial
University of Michigan and the Michigan OPO, Gift of Life Michigan, are leading the collaboration among the three transplant centers in the area. The collaboration between the OPO who will perfuse the lungs with STEEN Solution™ using the XPS™, and the transplant center that will perform the lung transplant is the first of its kind in the USA. The aim of the collaboration is to increase the utilization of lungs and give transplants to more patients with severe lung disease.
Last week the centers completed their XVIVO Perfusion System (XPS™) training during a two day course. The Michigan centers will start enrolling patients into the NOVEL study in the beginning of 2014. There continues to be a great interest in the USA for the STEEN Solution™ EVLP method, the XPS™ and to participate in the NOVEL study.
"We are pleased that more well-known clinical transplantation centers have joined the NOVEL trial and that the connected OPO has invested in an XPS™. This collaboration is first of its kind in the US and will increase the utilization of lungs and give transplants to more patients with severe lung disease, since one OPO can support multiple transplant centers. This is a very interesting model which has the potential to speed up the introduction of EVLP in the USA and it may become the dominating model in the future" says Dr Magnus Nilsson CEO of XVIVO Perfusion.
December 19, 2013
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on December 19, 2013 at 2:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.